These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11472235)

  • 1. Biological applications of hammerhead ribozymes as anti-viral molecules.
    Lustig B; Jeang KT
    Curr Med Chem; 2001 Aug; 8(10):1181-7. PubMed ID: 11472235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR.
    Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
    Rossi JJ; Elkins D; Zaia JA; Sullivan S
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):183-9. PubMed ID: 1540406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
    Rossi JJ; Sarver N
    Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of gene expression with ribozymes.
    Marschall P; Thomson JB; Eckstein F
    Cell Mol Neurobiol; 1994 Oct; 14(5):523-38. PubMed ID: 7621511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate.
    Goodchild J; Kohli V
    Arch Biochem Biophys; 1991 Feb; 284(2):386-91. PubMed ID: 1989522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
    Macejak DG; Jensen KL; Jamison SF; Domenico K; Roberts EC; Chaudhary N; von Carlowitz I; Bellon L; Tong MJ; Conrad A; Pavco PA; Blatt LM
    Hepatology; 2000 Mar; 31(3):769-76. PubMed ID: 10706571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.
    Yu M; Ojwang J; Yamada O; Hampel A; Rapapport J; Looney D; Wong-Staal F
    Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6340-4. PubMed ID: 8327516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of hammerhead ribozymes as antiviral tools].
    Rola M; Kuźmak J
    Postepy Biochem; 2001; 47(4):282-91. PubMed ID: 12046259
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-function relationship of hammerhead ribozymes as probed by 2'-modifications.
    Pieken WA; Olsen DB; Aurup H; Williams DM; Heidenreich O; Benseler F; Eckstein F
    Nucleic Acids Symp Ser; 1991; (24):51-3. PubMed ID: 1841379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo.
    Taylor NR; Kaplan BE; Swiderski P; Li H; Rossi JJ
    Nucleic Acids Res; 1992 Sep; 20(17):4559-65. PubMed ID: 1408757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozyme: a clinical tool.
    Khan AU
    Clin Chim Acta; 2006 May; 367(1-2):20-7. PubMed ID: 16426595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribozymes: a new frontier in anti-HIV strategy.
    Sarver N
    Antisense Res Dev; 1991; 1(4):373-8. PubMed ID: 1821659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.